File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors

TitleA prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors
Authors
Keywordsautoimmunity
COVID-19
interferons
post-acute COVID-19 syndrome
thyroid function tests
Issue Date3-Jan-2023
PublisherSpringer
Citation
Endocrine, 2023, v. 80, n. 2, p. 380-391 How to Cite?
Abstract

Abstract

Purpose: We evaluated the evolution of thyroid function and autoimmunity among COVID-19 survivors over 6 months in relation to interferon beta-1b treatment and long COVID.

Methods: We included COVID-19 survivors managed in a major COVID-19 centre between July 2020 and May 2021 who were reassessed three and/or six months after acute COVID-19. Thyroid function tests (TFTs) and anti-thyroid antibody titres were measured at acute COVID-19, 3-month and 6-month.

Results: 250 COVID-19 survivors were included (mean age 52.7 years, 50.4% men). Persistent thyroid function abnormalities were more likely in those with abnormal TFTs in acute COVID-19 (P < 0.001). Among 51 patients with abnormal TFTs in acute COVID-19, 82.4% resolved upon follow-up. Of 199 patients with normal TFTs in acute COVID-19, only 4.5% had incident abnormal TFTs, more likely in interferon-treated patients (P = 0.044) and none clinically overt. Among 129 patients with complete 6-month follow-up for anti-thyroid antibody titres, there was no significant change overall, except for modest increase in anti-thyroid antibody titres among the 84 interferon-treated patients (P < 0.05 at both 3 months and 6 months). Long COVID occurred in 19.5% and 10.4% at 3 and 6 months respectively, where TFTs and anti-thyroid antibody titres were not predictive of its occurrence.

Conclusion: Over 6 months, most abnormal TFTs in acute COVID-19 resolved, with no significant incident thyroid dysfunction. SARS-CoV-2 infection did not lead to change in thyroid autoimmunity, while interferon treatment was associated with modest increase in anti-thyroid antibody titres. Thyroid function and anti-thyroid antibodies did not play a significant role in long COVID.

Keywords: COVID-19; autoimmunity; interferons; post-acute COVID-19 syndrome; thyroid function tests.


Persistent Identifierhttp://hdl.handle.net/10722/333949
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.844
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLui, DTW-
dc.contributor.authorTsoi, KH-
dc.contributor.authorLee, CH-
dc.contributor.authorCheung, CYY-
dc.contributor.authorFong, CHY-
dc.contributor.authorLee, ACH-
dc.contributor.authorTam, AR-
dc.contributor.authorPang, PLY-
dc.contributor.authorHo, TY-
dc.contributor.authorLaw, CY-
dc.contributor.authorLam, CW-
dc.contributor.authorTo, KKW-
dc.contributor.authorChow, WS-
dc.contributor.authorWoo, YC-
dc.contributor.authorHung, IFN-
dc.contributor.authorTan, KCB-
dc.contributor.authorLam, KSL-
dc.date.accessioned2023-10-10T03:14:50Z-
dc.date.available2023-10-10T03:14:50Z-
dc.date.issued2023-01-03-
dc.identifier.citationEndocrine, 2023, v. 80, n. 2, p. 380-391-
dc.identifier.issn1355-008X-
dc.identifier.urihttp://hdl.handle.net/10722/333949-
dc.description.abstract<h2>Abstract</h2><p><strong>Purpose: </strong>We evaluated the evolution of thyroid function and autoimmunity among COVID-19 survivors over 6 months in relation to interferon beta-1b treatment and long COVID.</p><p><strong>Methods: </strong>We included COVID-19 survivors managed in a major COVID-19 centre between July 2020 and May 2021 who were reassessed three and/or six months after acute COVID-19. Thyroid function tests (TFTs) and anti-thyroid antibody titres were measured at acute COVID-19, 3-month and 6-month.</p><p><strong>Results: </strong>250 COVID-19 survivors were included (mean age 52.7 years, 50.4% men). Persistent thyroid function abnormalities were more likely in those with abnormal TFTs in acute COVID-19 (P < 0.001). Among 51 patients with abnormal TFTs in acute COVID-19, 82.4% resolved upon follow-up. Of 199 patients with normal TFTs in acute COVID-19, only 4.5% had incident abnormal TFTs, more likely in interferon-treated patients (P = 0.044) and none clinically overt. Among 129 patients with complete 6-month follow-up for anti-thyroid antibody titres, there was no significant change overall, except for modest increase in anti-thyroid antibody titres among the 84 interferon-treated patients (P < 0.05 at both 3 months and 6 months). Long COVID occurred in 19.5% and 10.4% at 3 and 6 months respectively, where TFTs and anti-thyroid antibody titres were not predictive of its occurrence.</p><p><strong>Conclusion: </strong>Over 6 months, most abnormal TFTs in acute COVID-19 resolved, with no significant incident thyroid dysfunction. SARS-CoV-2 infection did not lead to change in thyroid autoimmunity, while interferon treatment was associated with modest increase in anti-thyroid antibody titres. Thyroid function and anti-thyroid antibodies did not play a significant role in long COVID.</p><p><strong>Keywords: </strong>COVID-19; autoimmunity; interferons; post-acute COVID-19 syndrome; thyroid function tests.</p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofEndocrine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectautoimmunity-
dc.subjectCOVID-19-
dc.subjectinterferons-
dc.subjectpost-acute COVID-19 syndrome-
dc.subjectthyroid function tests-
dc.titleA prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors-
dc.typeArticle-
dc.identifier.doi10.1007/s12020-022-03281-8-
dc.identifier.scopuseid_2-s2.0-85145499907-
dc.identifier.volume80-
dc.identifier.issue2-
dc.identifier.spage380-
dc.identifier.epage391-
dc.identifier.eissn1559-0100-
dc.identifier.isiWOS:000907082000001-
dc.identifier.issnl1355-008X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats